skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection

Review

(2203) Views  (825) Full article downloads

Authors: Hans-Jürgen Stellbrink

Published Date July 2009 Volume 2009:4 Pages 149 - 158
DOI: http://dx.doi.org/10.2147/CE.S6009

Hans-Jürgen Stellbrink

Infektionsmedizinisches Centrum Hamburg (iCH), Hamburg, Germany

Introduction: Etravirine is a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) specifically designed to suppress the replication of viruses resistant to the three currently approved NNRTIs efavirenz, nevirapine, and delavirdine.

Aims: To assess the evidence for the place of etravirine in the treatment of HIV-1 infection.

Evidence review: In combination with a ritonavir-boosted protease inhibitor etravirine has demonstrated high antiviral activity against strains exhibiting up to three NNRTI resistance mutations. The drug appears to be well tolerated, with only nausea and rash occuring significantly more frequently with etravirine compared with placebo. Of note, neuropsychologic side effects that frequently limit the use of efavirenz were not reported more frequently with etravirine.

Place in therapy: Given its high activity against most NNRTI-resistant strains and its very good tolerability, etravirine is of high value for pretreated patients with NNRTI resistance and protease inhibitor exposure. Efforts should be made to demonstrate activity in switching strategies (due to toxicity) and earlier lines of failure or in the setting of primary NNRTI resistance in order to explore the potential of the drug beyond salvage therapy.

Keywords: etravirine, HIV-1, evidence






 

Other articles by Dr Hans-Juergen Stellbrink



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Indacaterol: a new once daily long-acting beta2 adrenoceptor agonist
Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Erratum
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University